60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Short Interest Up 133.2% in November

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) was the target of a significant increase in short interest in November. As of November 15th, there was short interest totalling 87,000 shares, an increase of 133.2% from the October 31st total of 37,300 shares. Based on an average daily trading volume, of 91,900 shares, the days-to-cover ratio is presently 0.9 days. Currently, 5.6% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, November 15th.

60 Degrees Pharmaceuticals Stock Performance

Shares of 60 Degrees Pharmaceuticals stock traded up $0.08 during trading hours on Thursday, reaching $1.09. The company’s stock had a trading volume of 263,660 shares, compared to its average volume of 241,440. 60 Degrees Pharmaceuticals has a one year low of $0.70 and a one year high of $18.36. The company’s 50 day simple moving average is $1.02 and its 200 day simple moving average is $0.76. The stock has a market cap of $2.51 million, a P/E ratio of -0.11 and a beta of 4.78.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.